img 614-636-4850
  • Follow us:


Biosortia Pharmaceuticals, Inc.

It is our mission to find new compounds for high priority unmet needs in pharmaceuticals. Advancement of the resulting derivatives of new previously unobtainable drug-like natural compounds from various natural aquatic microbiomes to a licensable revenue event near IND (investigational new drug - a start of development and the end of discovery) is the company’s business. The initial focus is immuno-oncology, oncology, and anti-inflammatory opportunities. We recognize the unparalleled access to the microbiome will present opportunities in various therapeutic areas with desperate needs for discovery.

The company has unique capabilities to recover massive amounts of microbiome (consortia of microorganisms biomass) in situ while preserving the integrity and access to the drug-like secondary metabolites opening the door to undiscovered chemistry from nature. The microbiome mining of the biomass begins with preservation, extraction, fractionation and initial testing. We are continuing to scale our capabilities to deconvolute the resulting chemical materials to match the bioprospecting harvesting capacity.

Funding is the major limit to Biosortia’s current capacity to discover and advance novel pharmaceutical discovery opportunities.


Biosortia Pharmaceuticals, Inc. focused efforts as drug discovery company in 2012. During 2012-14 the company worked hard to adapt and advance the original AVS technology for the in situ recovery of microorganisms. Proof and technological improvement of deep access to the dark chemical material of secondary metabolites were conducted by our scientists simultaneously. The original technology was supported by ARPA-E (Advanced Research Project Agency of the U.S. Department of Energy) during 2009-2011.

By the mid-2015, the company completed of the final designs of the proprietary harvesting technology along with the construction of a full-scale system. Biosortia’s team recognized the historical success of finding drug-like compounds from the minuscule number of culturable micro-organisms (the 1%) and believed a substantial increase in access to unculturable microorganisms (the 99%) would equate to more opportunities to find new drugs. The belief was simple: if you could recover unculturable microorganisms on a scale to obtain the actual chemistry, it would open the door to discovery, much like the Hubble telescope opened the doors to the previously unseen Universe.

Biosortia unlocks the aquatic microbial environment, the new drug frontier of discovery in a new and completely different strategy than researchers have ever pursued.